Denne selvbegrænsning skyldes sandsynligvis tabet af dibotermin alfa fra implantationsstedet samt tilstedeværelsen af BMP- hæmmere i det omgivende væv.
This self-limitation is likely due to the loss of dibotermin alfa from the implant site, as well as the presence of BMP inhibitors in the surrounding tissues.